Qoly

Based in Japan, Qoly develops micro-surgery assistance robots that enhance surgical precision and safety, addressing the challenges of specialized surgeon availability and improving patient access to high-quality surgical care. Founded in 2025 in Tokyo, Japan, Qoly specializes in creating advanced micro-surgery assistance robots. The company has successfully completed one deal, with its most recent funding occurring on February 6, 2026. During this funding round, Qoly raised JPY 1.

8 billion through a Series A round, co-led by Fast Track Initiative and MedVenture Partners, alongside participation from Sony Group and the Development Bank of Japan. Qoly Corporation specializes in the development, manufacturing, and support of micro-surgery assistance robots and related products. The core offerings are designed to enhance the precision and safety of surgical procedures, particularly in micro-surgery, which involves complex operations conducted under a microscope. These advanced robotic systems augment the capabilities of skilled surgeons, allowing for intricate procedures to be performed with greater accuracy and reduced risk to patients.

Qoly targets healthcare institutions and surgical centers, focusing on markets such as Japan while considering expansion into other regions requiring innovative surgical solutions. Qoly Corporation's revenue model is built around the sale and support of its micro-surgery assistance robots. Transactions typically occur through direct sales to hospitals and surgical clinics, where institutions invest in technology to enhance their surgical capabilities. The company structures its revenue streams through B2B transactions, including potential partnerships with healthcare providers and distributors of medical technology.

Pricing plans for robotic systems are customized to meet institutional needs, considering the complexity and features of the equipment, as well as ongoing support and training services provided by Qoly. In February 2026, Qoly raised JPY 1. 8 billion in Series A funding, which will be utilized to advance the development of its micro-surgery assistance robots, strengthen commercialization activities, expand clinical implementation, and accelerate technology integration. The company is also focusing on launching new products designed to enhance surgical capabilities and is exploring market expansion into regions outside of Japan to further its reach.

These initiatives are aimed at improving accessibility to high-quality surgical care worldwide.